Amgen: Strong growth company with a challenging future
Since it was founded in 1980, Amgen has established itself as a leading global biotechnology company and built increasingly strong human therapeutics brands as well as state of the art manufacturing facilities. This case study analyses the company's recent financial performance, evaluates the strategies that have helped it become a global leader, and explores what the future may hold.
Features and benefits
- Investigation of Amgen’s success and a detailed analysis of its rise to be one of the most innovative biotechnology companies in the world.
- Parallel comparisons in terms of R&D, stock market and financial performance to identify its strengths and weaknesses among its peers.
- Analysis of the challenges that Amgen faces both internally and externally.
- The case study also focuses on the R&D and acquisition strategy of the company.
Your key questions answered
- Since it was founded by William K. (Bill) Bowes and associates in 1980, Amgen has grown into a $120 billion company in just 35 years, generating significant profit in the process. The company’s impressive financial numbers have generated excellent share price performance, but the company does face a number of challenges.
- Amgen has not only enjoyed rapid organic growth due to its excellent R&D, a number of valuable acquisitions have also been proven to be instrumental to its expansion in terms of product portfolio and revenue over the years. This strategy remains a central part of the company’s plans.
- How did Amgen become the world's leading Biotechnology company?
- What are the key challenges the company now faces?
- CONSISTENT GROWTH ACCOMPANIED WITH SIGNIFICANT CHALLENGES
- AMGen to Amgen
- Rapid growing, profitable multi-billion dollar business
- Profitable growth
- Reliance on Neulasta and ENBREL
- Dependence on North America
- Strong stock market performance
- FOCUSED AND WELL-MANAGED R&D
- Amgen: An innovative human therapeutics company
- Organic growth stimulated by committed R&D investment
- Acquisitions continues to reap great results
- BOTH INTERNAL AND EXTERNAL CHALLENGES AHEAHD
- Challenges within the organization
- Inability to produce blockbuster drugs
- Litigation settlements hurt Amgen’s financial performance
- Difficult external challenges ahead
- Problematic acquisition
- The rise of Gilead
- Opportunity coincides with challenge for Amgen
- Further Reading
- Ask the analyst
- About MarketLine